The Dawn of a New Era: Emerging Therapeutic Strategies in the Diagnosis and Management of NASH

 

 

PROGRAM OVERVIEW

Nonalcoholic fatty liver disease (NAFLD) affects 24% of the American population and is projected to be the cause of nearly 800,000 excessive liver deaths from 2015 to 2030. Nonalcoholic steatohepatitis (NASH), the aggressive form of NAFLD, is a growing cause of cirrhosis and hepatocellular carcinoma and increasingly an indicator for liver transplantation. Healthcare providers would benefit from education on current epidemiologic and demographic data to enhance NASH identification, along with information on the use of liver biopsy and complementary noninvasive modalities to diagnose, stage, and monitor NAFLD/NASH progression.

FACULTY

Steven L. Flamm, MD
Professor of Medicine
Chief, Transplant Hepatology
Feinberg School of Medicine
Northwestern University
Chicago, Illinois

 

Release date: July 1, 2020
Expiration date: July 1, 2021
Estimated time to complete activity: 0.75 hour(s)

 

TARGET AUDIENCE

This educational activity addresses the needs of gastroenterologists, hepatologists, and other healthcare professionals involved in the diagnosis and treatment of NASH.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

  • Employ current epidemiologic and demographic data to enhance NASH identification
  • Apply liver biopsy and complementary noninvasive modalities for NAFLD/NASH diagnosis, staging, and monitoring
  • Describe new insights into the pathophysiology of NAFLD/NASH progression that inform the development of emerging NASH therapies and biomarkers
  • Discuss the safety and efficacy of emerging therapies undergoing clinical development for NASH
DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of July 1, 2020 through July 1, 2021, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 75% or better.

MEDIA

Internet

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or information@integrityce.com.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Steven Flamm, MD
Consulting Fees: Intercept Pharmaceuticals
Contracted Research: Intercept Pharmaceuticals

The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Intercept Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Windows 98, 2000, XP, 2003, Vista, and 7
Internet Explorer 6/7
Firefox 2
Mozilla 1.7 or higher
Netscape 8.1 or higher
Flash Player 10

Mac OS X 10.3, 10.4
Safari 1.3 (Mac OS 10.3)
Safari 2.0 or higher (Mac OS 10.4)
Firefox 2
Flash Player 10
Use of Internet Explorer browser is not recommended.

Click here for more information on minimum system requirements.

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

PROVIDER STATEMENT

Provided by Integrity Continuing Education, Inc.

SUPPORTER ACKNOWLEDGEMENT

Supported by an educational grant from Intercept Pharmaceuticals.

Continue to Pretest